Document Detail


Fragile X syndrome: from molecular genetics to therapy.
MedLine Citation:
PMID:  19724010     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Fragile X syndrome, the main cause of inherited mental retardation, is caused by transcriptional silencing of the fragile X mental retardation gene, FMR1. Absence of the associated protein FMRP leads to the dysregulation of many genes creating a phenotype of ADHD, anxiety, epilepsy and autism. The core aim of this review is to summarise two decades of molecular research leading to the characterisation of cellular and molecular pathways involved in the pathology of this disease and as a consequence to the identification of two new promising targets for rational therapy of fragile X syndrome, namely the group 1 metabotrope glutamate receptors (Gp1 mGluRs) and the gamma-amino butyric acid A receptors (GABA(A)Rs). As no current clinical treatments are directed specifically at the underlying neuronal defect due to absence of FMRP, this might open new powerful therapeutic strategies.
Authors:
C D'Hulst; R F Kooy
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of medical genetics     Volume:  46     ISSN:  1468-6244     ISO Abbreviation:  J. Med. Genet.     Publication Date:  2009 Sep 
Date Detail:
Created Date:  2009-09-02     Completed Date:  2009-12-31     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  2985087R     Medline TA:  J Med Genet     Country:  England    
Other Details:
Languages:  eng     Pagination:  577-84     Citation Subset:  IM    
Affiliation:
Department of Medical Genetics, University of Antwerp, Antwerp, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Fragile X Mental Retardation Protein / chemistry,  genetics,  metabolism
Fragile X Syndrome / genetics*,  metabolism,  therapy*
Humans
Chemical
Reg. No./Substance:
139135-51-6/Fragile X Mental Retardation Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The development of an objective model to assess arthroscopic performance.
Next Document:  Echinocandins: the newest class of antifungals.